Nanographene-constructed carbon nanofibers grown on graphene sheets by chemical vapor deposition: high-performance anode materials for lithium ion batteries.

We report on the fabrication of 3D carbonaceous material composed of 1D carbon nanofibers (CNF) grown on 2D graphene sheets (GNS) via a CVD approach in a fluidized bed reactor. Nanographene-constructed carbon nanofibers contain many cavities, open tips, and graphene platelets with edges exposed, providing more extra space for Li(+) storage. More interestingly, nanochannels consisting of graphene platelets arrange almost perpendicularly to the fiber axis, which is favorable for lithium ion diffusion from different orientations. In addition, 3D interconnected architectures facilitate the collection and transport of electrons during the cycling process. As a result, the CNF/GNS hybrid material shows high reversible capacity (667 mAh/g), high-rate performance, and cycling stability, which is superior to those of pure graphene, natural graphite, and carbon nanotubes. The simple CVD approach offers a new pathway for large-scale production of novel hybrid carbon materials for energy storage.

[Association between expressions of HSP70, HSP90 and efficacy of chemotherapy in colorectal cancer patients with unresectable liver metastasis].

OBJECTIVE: To investigate the association between expressions of HSP70, HSP90 and efficacy of chemotherapy in colorectal cancer patients with unresectable liver metastasis. METHODS: Data of 52 colorectal cancer cases, whose primary colorectal focuses were resected but hepatic metastatic tumors were unresectable, were reviewed retrospectively. All the patients underwent FOLFOX4 regimen well. Immunohistochemistry assay was applied to determine the expressions of HSP70 and HSP90 in primary focus tissues. The number and size of hepatic metastatic tumors pre- and post-chemotherapy were compared by CT scanning. RESULTS: Partial remission(PR) rate was 33.3% in cases with up-regulated expression of HSP70, while 64.5% in cases with down-regulated expression of HSP70, whose difference was significant. PR rate was 50% in cases with up-regulated expression of HSP90, and 53.1% in the others with down-regulated expression of HSP90, whose difference was not significant. CONCLUSIONS: FOLFOX4 regimen has advantages in cases with lower HSP70 expression over those with higher HSP70 expression. HSP90 expression level is not associated with the efficacy of FOLFOX4 regimen.